Comparative incidence of peripheral neuropathy associated with taxane chemotherapy in patients with breast cancer: A network meta-analysis.
Samineh Beheshtirouy, Zeinab Nikniaz, Saba Ghaffary et al.
✦ AI-curated · Sources linked
In 30 seconds
This Bayesian network meta-analysis compared taxane-associated peripheral neuropathy in females with breast cancer. It included 27 studies and 12,101 patients, assessing docetaxel, cabazitaxel, nab-paclitaxel, liposomal paclitaxel and paclitaxel injection concentrate for nanodispersion against paclitaxel. Nab-paclitaxel was associated with higher neuropathy incidence than paclitaxel (OR 1.74, CrI 1.22-2.48), while docetaxel (OR 0.626, CrI 0.441-0.881) and cabazitaxel (OR 0.158, CrI 0.0664-0.375) were associated with lower incidence. Differences for liposomal paclitaxel and PICN were not significant.
Key findings
- Compared with paclitaxel, nab-paclitaxel was associated with higher peripheral neuropathy incidence (OR: 1.74, CrI: 1.22-2.48).
- Docetaxel (OR: 0.626, CrI: 0.441-0.881) and cabazitaxel (OR: 0.158, CrI: 0.0664-0.375) were associated with lower incidence than paclitaxel.
- Liposomal paclitaxel and PICN did not differ significantly from paclitaxel in peripheral neuropathy incidence.
Why it matters
Peripheral neuropathy is a common taxane toxicity, and its incidence differed across agents in this analysis. These comparative estimates can help frame discussions of toxicity when taxane options are being considered for females with breast cancer, while recognising that the findings describe pooled comparative evidence rather than establishing an individual patient's risk.